PL3538528T3 - Amidy pirolu jako inhibitory integryny alfa v - Google Patents

Amidy pirolu jako inhibitory integryny alfa v

Info

Publication number
PL3538528T3
PL3538528T3 PL17801236T PL17801236T PL3538528T3 PL 3538528 T3 PL3538528 T3 PL 3538528T3 PL 17801236 T PL17801236 T PL 17801236T PL 17801236 T PL17801236 T PL 17801236T PL 3538528 T3 PL3538528 T3 PL 3538528T3
Authority
PL
Poland
Prior art keywords
alpha
integrin inhibitors
pyrrole amides
pyrrole
amides
Prior art date
Application number
PL17801236T
Other languages
English (en)
Polish (pl)
Inventor
Guohua Zhao
James Mignone
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3538528T3 publication Critical patent/PL3538528T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
PL17801236T 2016-11-08 2017-11-07 Amidy pirolu jako inhibitory integryny alfa v PL3538528T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418833P 2016-11-08 2016-11-08
PCT/US2017/060392 WO2018089360A1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors
EP17801236.5A EP3538528B1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
PL3538528T3 true PL3538528T3 (pl) 2021-05-31

Family

ID=60409438

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17801236T PL3538528T3 (pl) 2016-11-08 2017-11-07 Amidy pirolu jako inhibitory integryny alfa v

Country Status (23)

Country Link
US (1) US10717736B2 (https=)
EP (1) EP3538528B1 (https=)
JP (1) JP7220653B2 (https=)
KR (1) KR102515507B1 (https=)
CN (1) CN110139864B (https=)
AU (1) AU2017359030A1 (https=)
BR (1) BR112019009293A2 (https=)
CA (1) CA3042693A1 (https=)
CY (1) CY1123893T1 (https=)
DK (1) DK3538528T3 (https=)
EA (1) EA201991124A1 (https=)
ES (1) ES2852351T3 (https=)
HR (1) HRP20210228T1 (https=)
HU (1) HUE053620T2 (https=)
IL (1) IL266469A (https=)
LT (1) LT3538528T (https=)
MX (1) MX377293B (https=)
PL (1) PL3538528T3 (https=)
PT (1) PT3538528T (https=)
RS (1) RS61453B1 (https=)
SI (1) SI3538528T1 (https=)
SM (1) SMT202100089T1 (https=)
WO (1) WO2018089360A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
AU2017359025A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors
CN110177787A (zh) 2016-12-29 2019-08-27 圣路易斯大学 整合素拮抗剂
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
FI3844162T3 (fi) 2018-08-29 2025-03-27 Morphic Therapeutic Inc Alfa v beeta6 -integriinin estäjiä
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
CR20230472A (es) * 2021-03-10 2024-03-21 Dice Molecules Sv Inc Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
EP1049693A1 (en) * 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
CZ20003672A3 (cs) 1998-04-10 2001-08-15 G. D. Searle & Co. Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu
WO2000009503A1 (en) 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
DE19939981A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
CZ20021508A3 (cs) * 1999-11-08 2002-10-16 Merck & Co., Inc. Způsob výroby imidazolidinonových derivátů
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
DK1539739T3 (da) 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1667668B1 (en) 2003-10-01 2008-07-02 MERCK PATENT GmbH Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
EP2049490A1 (en) 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
WO2011090929A1 (en) * 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
NZ603789A (en) 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
HRP20171873T1 (hr) * 2013-02-07 2018-02-23 Scifluor Life Sciences, Inc Fluorinirani antagonisti integrina
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use

Also Published As

Publication number Publication date
KR102515507B1 (ko) 2023-03-28
MX377293B (es) 2025-03-07
JP7220653B2 (ja) 2023-02-10
US20190256512A1 (en) 2019-08-22
EA201991124A1 (ru) 2019-10-31
US10717736B2 (en) 2020-07-21
HRP20210228T1 (hr) 2021-03-19
SI3538528T1 (sl) 2021-03-31
KR20190076031A (ko) 2019-07-01
PT3538528T (pt) 2021-02-16
WO2018089360A1 (en) 2018-05-17
SMT202100089T1 (it) 2021-03-15
RS61453B1 (sr) 2021-03-31
DK3538528T3 (da) 2021-02-15
CY1123893T1 (el) 2022-05-27
CN110139864B (zh) 2022-08-23
BR112019009293A2 (pt) 2019-07-30
CN110139864A (zh) 2019-08-16
EP3538528A1 (en) 2019-09-18
ES2852351T3 (es) 2021-09-13
CA3042693A1 (en) 2018-05-17
MX2019005233A (es) 2019-08-12
IL266469A (en) 2019-07-31
LT3538528T (lt) 2021-03-10
HUE053620T2 (hu) 2021-07-28
JP2020500182A (ja) 2020-01-09
AU2017359030A1 (en) 2019-06-20
EP3538528B1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
IL266469A (en) Pyrrol-amides as alpha-v-integrin inhibitors
ZA201905811B (en) Novel inhibitors
IL266470A (en) Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitors
IL255246A0 (en) Heterocyclic amides as kinase inhibitors
IL258180B (en) Heterocyclic compounds and their uses
IL272649B (en) AHR inhibitors and their uses
IL266465A (en) Azole amides and amines as alpha five integrin inhibitors
GB201605126D0 (en) Inhibitors and their uses
GB201708652D0 (en) Novel compounds and uses
IL246987A0 (en) Heteroaryl amides, preparations containing it and their uses
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
ZA201907136B (en) Ip6k inhibitors
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
IL275375A (en) Pyrrolidine amides II are converted
IL275374A (en) Pyrrolidine amides I are converted
IL265139B (en) Dopamine-b-hydroxylase inhibitors
IL254916B (en) Inhibitors and their uses
IL262400A (en) Erbb inhibitors and uses thereof
GB201612860D0 (en) Inhibitors
IL251077B (en) Integrin inhibitors and their use
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
PL3209743T3 (pl) Zastosowanie foliowych materiałów licowych do polimerowego opakowania
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL251078A0 (en) Integrin inhibitors and their use
PL3268356T3 (pl) Związki heterocykliczne i sposoby ich stosowania